RTN-001 is under clinical development by Retension Pharmaceuticals and currently in Phase II for Hypertension. According to GlobalData, Phase II drugs for Hypertension have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RTN-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RTN-001 overview
RTN-001 is under development for the treatment of hypertension. KD-027 is administered through oral route. It acts by targeting phosphodiesterase 5. The drug candidate is developed based on Pharmacomer Technology Platform. It was under development for the treatment of Raynaud's disease, erectile dysfunction and endothelial dysfunction.
Retension Pharmaceuticals overview
Retension Pharmaceuticals operates within the pharmaceuticals and healthcare industry, It specializes in biotechnology solutions and develop drugs which targets resistant hypertension disorders. The company is headquartered in McLean, Virginia, the US.
For a complete picture of RTN-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
